Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To determine the response rate, complete and partial, of patients with indolent lymphoma
receiving Rituxan and BEAM with autologous stem cell transplant.